Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Antares Pharma, Inc.

Antares Pharma, Inc. (ATRS) Stock Overview

Explore Antares Pharma, Inc.’s financial performance, market position, analyst ratings, and future outlook.

ATRS●NASDAQ
HealthcareMedical - Instruments & Supplies
$5.59
$0.010(0.18%)
U.S. Market opens in 14h 26m

Antares Pharma, Inc. (ATRS)

Meyka AI Score

Z

Key Financials

Market Cap0
P/E Ratio20.70
EPS (TTM)$0.37
ROE0.31%
Fundamental Analysis

AI Price Forecasts

1 Month$6.00
3 Months$6.47
1 Year Target$7.27

ATRS Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Antares Pharma, Inc. (NASDAQ: ATRS) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Antares Pharma, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of ATRS on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $7.27 for the NASDAQ listing.

Key metrics behind Antares Pharma, Inc.'s NASDAQ-traded stock include a P/E ratio of 20.70 and a market capitalization of 0. Combined with our AI analysis, these give both institutional and retail investors a clear view of ATRS on the NASDAQ.

Price Performance (NASDAQ: ATRS)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
N/A
6-Month Change
N/A
Year-to-Date (YTD) Change
N/A
1-Year Change
N/A
3-Year Change
N/A
5-Year Change
98.23%
All-Time (Max) Change
69.39%

Contact Information

https://www.antarespharma.com
16093593020
SUITE 300, 100 PRINCETON SOUTH, Ewing, NJ, 08628

Company Facts

2,010 Employees
IPO DateOct 3, 1996
CountryUS

Frequently Asked Questions